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We have investigated the effects of inflammatory mediators and /3-adrenoceptor agonists on the adenylyl cyclase responsive- 
ness in alveolar macrophages from control subjects, patients uffering from chronic obstructive pulmonary disease (COPD) and 
asthmatics. Basal cyclic AMP (cAMP) levels in alveolar macrophages from COPD patients were significantly elevated (plus 42%) 
as compared to controls. In addition, the adenylyl cyclase responsiveness to prostaglandin E2, histamine and the/3-adrenoceptor 
agonist salbutamol was significantly impaired in alveolar macrophages from COPD patients and asthmatics. The lipid mediator 
platelet activating factor showed no effect on cAMP production in all three alveolar macrophage populations. Furthermore, the 
cAMP-enhancing effects of isoprenaline, salbutamol and histamine appeared to be mediated via/32-adrenoceptors andhistamine 
H2-receptor subtypes respectively. Taken together, these data suggest an intrinsic desensitization phenomenon i alveolar 
macrophages from COPD patients and asthmatics. 
Alveolar macrophages; cAMP; Chronic obstructive pulmonary disease; Asthma; Adenylyl cyclase; Inflammatory mediators; 
/3-Adrenoceptor agonists 
I. Introduction 
Pulmonary inflammation is incontrovertibly associ- 
ated with chronic obstructive pulmonary disease 
(COPD) and asthma (Chung, 1986). Within the com- 
plex pathophysiological processes, alveolar macro- 
phages exert a predominant role. Firstly, these cells act 
as scavengers in the first line of host defense by means 
of phagocytosis land related features like the produc- 
tion and release of reactive oxygen radicals and lyso- 
zomal enzymes (Fels and Cohn, 1986; Takemura and 
Werb, 1984). Secondly, alveolar macrophages retain a 
large potency to modulate the activity of other pul- 
monary cells via the release of inflammatory mediators 
like prostaglandins, leukotrienes and platelet activating 
factor (Morley et al., 1979; Arnoux et al., 1980; Fels et 
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al., 1982; MacDermot et al., 1984; Martin et al., 1984) 
and cytokines like interleukin-1 (IL-1) and tumor 
necrosis factor-a (TNF-a) (reviewed by Sibille and 
Reynolds, 1989; Kelley, 1990). 
With respect o functional activity between alveolar 
macrophages from controls, COPD patients and asth- 
matics, several conflicting results have been reported. 
Thus, eicosanoid release from alveolar macrophages of
asthmatics and COPD patients has been shown to be 
impaired (Godard et al., 1982), unaltered (Balter et al., 
1988) or even enhanced (Damon et al., 1989; Chavis et 
al., 1991). Furthermore, the release of platelet activat- 
ing factor (PAF), oxygen radicals and ¢3-glucuronidase 
appears to be enhanced in alveolar macrophages from 
asthmatics (Tonnel et al., 1986; Arnoux et al., 1987; 
Cluzel et al., 1987). 
Pulmonary mediators and other substances like hor- 
mones and drugs interact with cells via specific surface 
receptors coupled to transmembrane signalling systems 
which produce several second messengers (reviewed by 
Barnes, 1987). Functional activity of alveolar 
macrophages (and cells in general) is largely associated 
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with intracellular levels of cyclic AMP (cAMP), a sec- 
ond messenger produced by the action of adenylyl 
cyclase. In general, high levels of cAMP coincide with 
down-regulation of functional activity (Bonta and Parn- 
ham, 1982). 
Though the effects of inflammatory mediators on 
general aspects of pulmonary inflammation have been 
dearly described, reports on their effects on alveolar 
macrophages remain scarce. Histamine, leukotrienes 
and PAF have potent bronchoconstrictive actions, 
stimulate mucus secretion and exert strong chemotactic 
potency for inflammatory cells (Goetzl and Pickett, 
1981; Hannah et al., 1981; Finney et al., 1985; Wardlaw 
et al., 1986; Persson, 1988). Prostaglandins of the E-type 
have mainly bronchodilating properties (Gardiner, 
1975). To further investigate the role of mediators in 
pulmonary inflammation, we performed studies on the 
effects of histamine, prostaglandin E 2 (PGE2), prosta- 
cyclin (PGI 2) and PAF on adenylyl cyclase responsive- 
ness in human alveolar macrophages from controls, 
COPD patients and asthmatics. In addition, the effects 
of the /3-adrenoceptor agonists isoprenaline and salbu- 
tamol (frequently used as anti-asthmatic drugs) on 
adenylyl cyclase responsiveness were determined as 
well. 
capacity (FVC) was 83 _+ 4.0% (percentage of predicted 
value). All of them were tobacco smokers (> 13 pack 
years), three received /3-sympathicomimetics and one 
corticosteroids. Bronchial asthma was diagnosed on the 
basis of clinical history, severity of airway obstruction 
(FEV 1 less than 70% of predicted value) and partial 
reversibility after inhalation of /3-adrenoceptor ago- 
nists. 
2.3. Isolation of ah~eolar macrophages 
BAL fluids were filtered through surgical gauze and 
centrifuged at 400 ×g (10 min, 4°C). If necessary, 
erythrocytes were lysed by hypo-osmotic shock. The 
pellet was resuspended in Gey balanced salt solution 
(GBSS), pH 7.4 and alveolar macrophages were puri- 
fied by density gradient centrifugation (400 x g, 30 
min, 4°C) using Ficoll-Isopaque (Nycomed, Oslo, Nor- 
way). After extensive washing, more than 95% of the 
isolated cell suspension consisted of alveolar 
macrophages as judged by May-Grfinwald-Giemsa 
staining. Viability of the ceils was assessed by dye 
exclusion using Trypan blue and alveolar macrophage 
suspensions with a viability exceeding 95% were used 
for the experiments. 
2. Materials and methods 2.4. Incubation procedure 
2.1. Subjects 
Smoking female volunteers (> 5 pack years, age 
23-37 years, mean age 30 years) were studied. None of 
the subjects had a history of pulmonary disorders or 
received any medication 2 months prior to the study. 
Informed consent for bronchoalveolar lavage (BAL) 
was obtained. BAL was performed under general anes- 
thesia using a fiber optic bronchoscope. Four subse- 
quent volumes of 50 ml sterile saline were instilled into 
a subsegmental bronchus of the right middle lobe, 
followed by gentle aspiration. The obtained BAL fluids 
were kept on ice until further isolation of alveolar 
macrophages. 
2.2. Patients 
The study included 12 COPD patients (seven fe- 
male, five male, ages 24-75 years, mean age 51 years) 
and two non-atopic asthmatics (female, ages 31 and 37 
years). Diagnosis of COPD patients (chronic bronchi- 
tis, n = 6; bronchial emphysema, n = 6) was based on a 
history of clinical symptoms, chest X-ray and pul- 
monary function tests. Mean forced expiratory volume 
(FEV 1) was 72 _+ 6.9% and mean forced expiratory vital 
1 ml samples of alveolar macrophages (10 ~') were 
incubated in GBSS at 37°C in the presence of 400/zM 
IBMX (3-isobutyl-l-methylxanthine, Janssen Chimica, 
Beerse, Belgium) with histamine (Pharmacy Depart- 
ment, Dijkzigt Hospital, Rotterdam, Netherlands), 
prostaglandin E 2 (PGE2), prostacyclin (PGI2), platelet 
activating factor (PAF), salbutamol or isoprenaline (all 
from Sigma, St. Louis, MO, USA) dissolved in GBSS 
buffer. In some experiments cell suspensions were 
preincubated for 10 min with propranolol (Ciba-Geigy, 
Basel, Switzerland), cimetidine (Sigma, St. Louis, MO, 
USA) or mepyramine (Rh6ne-Poulenc, Paris, France). 
Following a 15 rain incubation, cells were spinned 
down and resuspended in 150 /zl Tris-HCl buffer (pH 
7.4) and boiled for 3 rain. Cellular content of cAMP 
was determined by radioimmunoassay using [3H]cAMP 
(Amersham, Amersham, UK) and a high-affinity bind- 
ing protein as described previously (Bonta et al., 1984). 
2.5. Statistical analysis 
Data are expressed as means_+ S.E.M. Statistical 
significance was evaluated by the unpaired Mann- 
Whitney U test. A P value of < 0.05 was considered 
significant. 
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3. Resul ts  
Table 1 shows the cellular differentiation of the 
BAL fluids from the three different groups of subjects 
(controls, COPD patients and asthmatics). Alveolar 
macrophages make up the majority of the recovered 
cells (91.5-95.5%) with a marked decrease in the per- 
centage in the BAL fluids from COPD patients and an 
increase in the number of lymphocytes, eosinophils and 
neutrophils. 
Basal cAMP levels were significantly higher (plus 
42%) in alveolar macrophages from COPD patients as 
compared to control alveolar macrophages, while alve- 
olar macrophages from (two) asthmatics howed the 
same level as controls (cf. table 2). 
The stimulatory effects of inflammatory mediators 
(PGE 2, PGI 2, PAF and histamine) and /3-sym- 
pathicomimetics (isoprenaline and salbutamol) on cyclic 
AMP production in different alveolar macrophage 
populations are depicted in figs. 1 and 2. Prostaglandin 
E 2 and histamine dose-dependently stimulated cAMP 
TABLE 1 
Cellular differentiation (in percentages) of BAL fluids from controls, 
COPD patients and asthmatics. 
Number of observations in parentheses. 
Controls COPD Asthmatics 
(22) patients (12) (2) 
Macrophages 95.5 + 0.6 87.2 _+ 3.6 * 91.5 _+ 0.5 
Lymphocytes 2.3 _+ 0.4 4.3 _+ 0.6 * 3.5 + 2.5 
Eosinophils 0.6_+0.2 1.9_+0.7 * 3.2_+2.5 
Neutrophils 0.3-+0.1 4.8+2.8 * 0.4-+0.9 
Mononuclear cells a 1.3 -+ 0.8 1.8 -+ 0.6 1.4 _+ 0.7 
a Other than macrophages or lymphocytes. 
* P < 0.05 as compared to controls. 
production in the three alveolar macrophage popula- 
tions, though less effectively in alveolar macrophages 
from COPD patients and asthmatics (cf. figs. la and ld 
respectively). Using PGI2, no difference in adenylyl 
cyclase responsiveness among the three different alveo- 
lar macrophage populations (cf. fig. lb) was observed. 
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Fig. 1. Cyclic AMP production in alveolar macrophages (AM) from control subjects (CTRL, open circles), COPD patients (COPD, open squares) 
and asthmatics (ASTHMA, closed squares) following a 15 min incubation with the inflammatory mediators PGE 2 (a), PGI 2 (b), PAF (c), and 
histamine (d) in the presence of 400 /xM IBMX. Prior to incubation with histamine, control alveolar macrophages were incubated with the 
Hrselect ive antagonist cimetidine 10 5 M (panel d, closed circles). Number of duplicate observations in parentheses. Data are expressed as 
mean absolute increase above basal cAMP level +_ S.E.M. (pmol/106 alveolar macrophages). * P < 0.05 as compared to controls. 
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TABLE 2 
Basal cAMP levels in alveolar macrophages from controls, COPD 
patients and asthmatics. 
Data are expressed as mean +_ S.E.M. (pmol /106 alveolar 
macrophages) from 22 (controls), 12 (COPD patients) and two 
(asthmatics) duplicate experiments. 
cAMP (pmol/10 ('alveolar macrophages) 
Controls 1.63 _+ 0.11 
COPD patients 2.31 _+ 0.28 * 
Asthmatics 1.57 _+ 0.93 
• P < 0.05 as compared to controls. 
The lipid mediator PAF does not affect cAMP levels in 
alveolar macrophages (cf. fig. lc). At the lowest con- 
centration (10-12 M), however, PAF tends to enhance 
cAMP production in alveolar macrophages from COPD 
patients (+ 15%) and asthmatics ( + 17%). 
The adenylyl cyclase responsiveness to isoprenaline 
and salbutamol shows similar results as the response of 
the inflammatory mediators. The non-selective /3- 
adrenoceptor agonist isoprenaline nhances cAMP lev- 
els in all three alveolar macrophage populations with 
the same potency (cf. fig. 2a), whereas the response to 
the /32-selective adrenoceptor agonist salbutamol is 
largely reduced in alveolar macrophages from COPD 
patients and asthmatics (cf. fig. 2b). 
The stimulatory effects of isoprenaline and salbuta- 
mol on cAMP production were completely blocked by 
propranolol 10 -5 M (cf. figs. 2a and 2b). Considering 
the high potency of salbutamol, /3z-adrenoceptors ap- 
pear to mediate this action. The histaminergic effect is 
attained by stimulation of histamine H 2 receptors as 
the H2-selective antagonist cimetidine (10 5 M) com- 
pletely reversed the effect (cf. fig. ld) while the H l- 
selective antagonist mepyramine (10 5 M) was in this 
respect not effective (results not shown). 
It should be mentioned that due to the poor avail- 
ability of alveolar macrophages from asthmatics, we 
were not able to determine the adenylyl cyclase re- 
sponsiveness more adequately in this alveolar 
macrophage population. 
4. Discussion 
Recently, we have shown in human alveolar 
macrophages that the/32-adrenergic agonist salbutamol 
and the phosphodiesterase inhibitor IBMX inhibited 
PGE 2 release and stimulated leukotriene B 4 (LTB 4) 
secretion via enhancement of intracellular cAMP levels 
(Beusenberg et al., submitted for publication). Hence, 
we were interested to determine whether inflammatory 
mediators and/3 sympathicomimetics showed the same 
potency to stimulate cAMP production in alveolar 
macrophages from controls, COPD patients and asth- 
matics. 
Cellular composition of BAL fluids from the three 
groups of subjects differed largely with respect o the 
number of alveolar macrophages, eosinophils, neu- 
trophils and lymphocytes which is in accordance with 
previous results. Thus, an increase in the number of 
predominantly eosinophils in BAL fluids from asthmat- 
ics has been reported by Wardlaw et al. (1988) and 
Tomioka et al. (1984) wherease in BAL fluids from 
COPD patients an increase of neutrophils has been 
reported (Martin et al., 1985). The increase in the 
number of lymphocytes in COPD patients and asthmat- 
ics (both groups consisting of non-allergic subjects) 
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Fig. 2. Cyclic AMP production in alveolar macrophages (AM) from control subjects (CTRL, open circles), COPD patients (COPD, open squares) 
and asthmatics (ASTHMA, closed squares) following a 15 min incubation with the /3-adrenoceptor agonists isoprenaline (Isop, panel a) and 
salbutamol (Salb, panel b) in the presence of 400/zM IBMX. Prior to incubation with the agonists, control alveolar macrophages were incubated 
with the non-selective /3-adrenoceptor antagonist propranolol (prop, 10 5 M, closed circles). Number of duplicate observations in parentheses. 
Data are expressed as mean absolute increase above basal cAMP level_+ S.E.M. (pmol/106 alveolar macrophages). * P < 0.05 as compared to 
controls. 
observed by us and others (Gonzalez et al., 1987; 
Metzger et al., 1987) suggests that these cells, besides 
alveolar macrophages, eosinophils and neutrophils, may 
play an important role in pulmonary inflammation. 
The present results show that initial basal cAMP 
levels differed largely between the alveolar macrophage 
populations. Alveolar macrophages from COPD pa- 
tients contained some 40% more cAMP than control 
alveolar macrophages whereas basal cAMP levels in 
alveolar macrophages from asthmatics howed no dif- 
ferences compared to controls. 
For different reasons, it is difficult to interpret our 
data on basal cAMP in alveolar macrophages from 
asthmatics with functional parameters as conflicting 
data have been reported. Thus, while some reports 
indicate altered functional activity (e.g. chemilumines- 
cence and arachidonic acid metabolism) in alveolar 
macrophages from asthmatics (Godard et al., 1982; 
Cluzel et al., 1987; Damon et al., 1989), others have 
reported similar results between alveolar macrophages 
from asthmatics and controls (Balter et al., 1988). In 
addition, our results were merely based on two asth- 
matics (which suggested no differences in basal cAMP 
levels). Whether  functional activity of alveolar 
macrophages from asthmatics indeed differs from con- 
trols remains to be established. 
One can only speculate about the origin of the 
enhanced basal cAMP levels in alveolar macrophages 
from COPD patients. Possibly, the persistent local 
inflammatory environment generates various media- 
tors, like PGE 2, PGI 2 and histamine which stimulate 
cAMP production in alveolar macrophages located in 
the alveolar compartment. Like in other tissues and 
cells (Remold-O'Donell,  1974; Meurs et al., 1985), such 
continuous exposure of alveolar macrophages to in- 
flammatory mediators, which may stimulate adenylyl 
cyclase, will ultimately induce a desensitization of the 
st imulatory  receptors .  Consequent ly ,  a lveolar 
macrophages will become less susceptible to respond to 
these inflammatory substances. The present data on 
the diminished responsiveness of the adenylyl cyclase- 
coupled signal transduction system to various media- 
tors and drugs suggest a heterologous desensitization 
phenomenon. The differences in potency between the 
/3-adrenoceptor agonists isoprenaline and salbutamol 
to stimulate adenylyl cyclase is in accordance with 
previous results. Using guinea pig alveolar macro- 
phages, we suggested that the observed ifferences are 
probably due to the partial agonistic effect of salbuta- 
mol (Beusenberg et al., 1989). 
The few data on alveolar macrophages from asth- 
matics presented here point to a similar desensitization 
of the adenylyl cyclase system in alveolar macrophages, 
suggesting that asthma shares some common im- 
munoregulatory- and inflammatory-related mecha- 
nisms with COPD. 
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Within the pathophysiology of asthma and COPD, 
data on the phenomenon of desensitization in pul- 
monary cells are limited and have been confined to 
mainly bronchial smooth muscles and blood leukocytes. 
It is suggested that diminished /3-adrenoceptor func- 
tion in asthmatics is probably a consequence of the 
active disease state (following allergen challenge) rather 
than an intrinsic component of asthma (reviewed by 
Nijkamp and Henricks, 1990). In the present report, 
however, we present evidence that a general (including 
/3-adrenoceptor) dysfunction of the adenylyl cyclase 
system in alveolar macrophages, an important cellular 
component within the pulmonary compartment, is a 
general and intrinsic feature of pulmonary inflamma- 
tion associated with asthma and COPD. 
Physiologically, the impaired responsiveness of the 
adenylyl cyclase system to stimulatory agents in alveo- 
lar macrophages from COPD patients and asthmatics 
would implicate that cellular functions of the alveolar 
macrophages which are affected by alterations in cAMP 
levels (like oxygen radical and enzyme production) are 
less susceptible to modulation by external factors. 
Whether this renders the alveolar macrophages more 
sensitive to external modulation via mechanisms dis- 
tinct from the adenylyl cyclase pathway remains to be 
investigated. 
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